Paratek Pharmaceuticals jumps as drug receives 'Fast Track' designation
21/06/2022 22:31
** Biopharmaceutical company Paratek Pharmaceuticals' shares
PRTK.O rise 13.2% to $2.14
** Co receives U.S. Food and Drug Administration's "Fast
Track" designation for oral and intravenous versions of its
antibiotic, Nuzyra
** If approved, drug will be used to treat pulmonary
Nontuberculous Mycobacterial (NTM) disease, a bacterial
infection that most commonly affects lungs
** Up to last close, stock had fallen ~58% YTD
(Reporting by Akash Sriram in Bengaluru)
((Akash.Sriram@thomsonreuters.com; https://twitter.com/hoodieonveshti;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million